⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112654 | 0.69 | — | — | |
| SCHEMBL831257 | 0.65 | — | — | |
| SCHEMBL1654819 | 0.65 | — | — | |
| SCHEMBL1650923 | 0.65 | — | — | |
| SCHEMBL1064651 | 0.65 | — | — | |
| SCHEMBL380104 | 0.65 | — | — | |
| SCHEMBL3955270 | 0.62 | — | — | |
| SCHEMBL3659172 | 0.62 | — | — | |
| SCHEMBL15201716 | 0.62 | — | — | |
| SCHEMBL14220796 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103371-A | EGFR inhibitor and preparation method and application thereof | 山东新时代药业有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-114213353-B | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2023-04-14 | — | — | CN | claimed |
| CN-115838370-A | EGFR inhibitor and preparation method and application thereof | 山东新时代药业有限公司 | 2023-03-24 | — | — | CN | claimed |
| CN-114989052-A | Guaiazuo thioether compound and preparation method thereof | 苏州大学 | 2022-09-02 | — | — | CN | claimed |
| EP-3969444-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | The Regents of the University of California (US) | 2022-03-23 | — | — | EP | claimed |
| CN-114213353-A | Aryl-oxazole-oxazoline compound and preparation method and application thereof | 贵州大学 | 2022-03-22 | — | — | CN | claimed |
| CN-113195483-A | Novel oxadiazole compound | PI工业有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-107405347-B | NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | 欧歌达有限公司 | 2021-05-25 | — | — | CN | claimed |
| WO-2020232056-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-19 | — | — | WO | claimed |
| US-10183948-B2 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | OGEDA SA (BE) | 2019-01-22 | — | — | US | claimed |
| US-7732162-B2 | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases | PROBIODRUG AG (DE) | 2010-06-08 | — | — | US | claimed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | claimed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | claimed |
| EP-1134283-B1 | Method for producing L-Phenylalanine | AJINOMOTO KK (JP) | 2005-09-14 | — | — | EP | claimed |
| EP-1542999-A1 | 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY | Pharmacia & Upjohn Company LLC (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004013137-A1 | 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-12 | — | — | WO | claimed |
| JP-2003502330-A | — | — | 2003-01-21 | — | — | JP | claimed |
| EP-1189905-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | claimed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | claimed |